Omthera Looks To Take Lead In Omega-3 Space, Armed With Data Showing Advantages Over Lovaza
This article was originally published in The Pink Sheet Daily
Executive Summary
Privately held New Jersey firm expects data from pivotal Phase III trial of Epanova during first half of 2012, with NDA to follow shortly.